No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LTH240816P17500
- 0.20
- 0.000.00%
15min DelayClose Jul 23 15:55 ET
0.00High0.00Low
0.20Open0.20Pre Close0 Volume3 Open Interest17.50Strike Price0.00Turnover64.66%IV17.93%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type-0.1102Delta0.0539Gamma105.40Leverage Ratio-0.0134Theta-0.0015Rho-11.62Eff Leverage0.0102Vega
Intraday
- 5D
- Daily
News
Craig-Hallum Maintains Life Time(LTH.US) With Buy Rating, Maintains Target Price $30
Express News | Life Time Group Holdings Inc : BofA Global Research Raises Price Objective to $25 From $23
Life Time Group Hldgs Analyst Ratings
Craig-Hallum Initiates Life Time(LTH.US) With Buy Rating, Announces Target Price $30
Express News | Life Time Group Holdings, Inc. : Craig-Hallum Initiates Coverage With Buy Rating and Target Price $30
Oppenheimer's Best SMID-cap Ideas: AI, Health, Obesity Drugs, and More
Comments
The stock appears overpriced with its high beta causing amplified price movements. Its optimistic future growth seems already factored into the current share price, making it potentially not the best time to buy as it has outpaced its industry peers.
Is There Now An Opportunity In Life Time Group Holdings, Inc. (NYSE:LTH)? 1
Despite lower forecasted growth, Life Time Group's P/S ratio is on par with industry peers, hinting investor loyalty. However, alignment of P/S ratio with the growth outlook could result in disappointment. Weak revenue outlook puts the share price at risk requiring positive change to justify P/S ratio.
$Life Time(LTH.US$ another good earnings yet they dumped it. Trash market.
Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%, ...
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%, ...
10
$Life Time(LTH.US$ New trend line confirmed? Higher lows with 3 touch points now on the 5 min chart
Read more